Avadim Technologies Named to the Inc. 500 List of Fastest-Growing Private Companies in America
Avadim Ranks No. 234 on the 2016 Inc. 500 List with Three-Year Sales Growth of 1,675%
Read this article directly on the Avadim website here.
Asheville, NC (August 17, 2016) – Avadim Technologies, Inc. (“Avadim”), a life sciences company delivering Pathogenesis Based Therapies (“PBTs”), which work to optimize the stratum corneum, integumentary functions, and the associated reactive tissue, today announced that Inc. Magazine has recognized the Company as one of the fastest growing private companies in America. Inc. Magazine today ranked Avadim # 234 on its 2016 Inc. 500 List, an exclusive ranking of the nation’s fastest-growing private companies.
The achievement has put Avadim in an elite group of companies who have previously been named to the Inc. 500 including Microsoft, Under Armour, Intuit, GoPro, Oracle, Timberland, Clif Bar, Patagonia, Zappos and many other well-known names gained early exposure as members of the Inc. 500. In addition to Avadim, the 2016 Inc. 500 list includes Dollar Shave Club, Square, ipsy, and Yeti Cooler.
Stephen Woody, Avadim Chairman and CEO, stated, “We are honored to be selected to join the respected list of the fastest-growing 500 private companies in America and we look forward to our continued growth and innovation. This accomplishment is a testament to the team, business model, strategy, and proprietary technology we have in place at Avadim. Going forward we will work closely with our customers and partners as we continue to address the gaps in global health including infection, neuromuscular disorders and wound care.”
About Avadim Technologies, Inc.:
Avadim Technologies, Inc. is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.